Nagi Bioscience

EPFL spin-off Nagi Bioscience has developed a device that allows rapid toxicology testing of new chemicals. It offers whole organism tests without falling under the animal test ban. The model organism, the 1mm worm C. elegans is introduced into the device on microfluidic chips. The device is able to measure different parameters for a large number of tests that run in parallel, a very effective and easy setup. Nagi sells its device to companies in the agrochemicals, cosmetics and pharma industries.
Nagi_New_Logo_Verve Ventures portfolio
Matteo Cornaglia about Verve Ventures
VERVE Ventures has been providing truly precious support to our activities over the last two years, with a focus on the development of Nagi’s network of investors, customers and advisors.
Founders / Management Matteo Cornaglia, Laurent Mouchiroud
Sectors Health & Bio, Diagnostics, Toxicology
Located in Switzerland
Co-Investors ZKB
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.